SCHEMBL30178438

SCHEMBL30178438

CSc1ccc(N)c(CCNC2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.49
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
VCP P55072 2/20 0.40
EPHX1 P07099 1/20 0.40
EPHX2 P34913 1/20 0.40
DPP4 P27487 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17870765 0.86 DRD4 (0.40) ALDH1A1KDM4ELMNAMAPK1
SCHEMBL30178331 0.85 ALDH1A1 (0.56) GPR119ALDH1A1NPC1MAPTMAPK1
SCHEMBL28644008 0.85 LMNA (0.35) GPR119ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL30178376 0.85 GPR119 (0.46) GPR119ALDH1A1KDM4ELMNANPC1
SCHEMBL1814017 0.83 KDM4E (0.48) GPR119ALDH1A1KDM4ELMNANPC1
SCHEMBL19873705 0.80 HTR4 (0.39) KDM4ELMNA
SCHEMBL16616311 0.79 ALDH1A1 (0.47) GPR119ALDH1A1KDM4ENPC1MAPT
SCHEMBL3166766 0.76 GPR119 (0.48) GPR119ALDH1A1KDM4ENPC1MAPT
SCHEMBL17803256 0.76 USP30 (0.48) GPR119ALDH1A1KDM4ENPC1MAPT
SCHEMBL2604335 0.75 KDM4E (0.53) GPR119ALDH1A1KDM4ELMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3708566-B1 NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2023-02-08 EP disclosed